Biogen lifts annual profit forecast as new treatments boost earnings
Updates shares, adds analyst comment in paragraph 4, CEO comment in paragraph 7 and graphic
By Mariam Sunny
Oct 30 (Reuters) - Biogen BIIB.O raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of its multiple sclerosis drugs.
However, the drugmaker's shares fell nearly 3%, as sales of some key treatments such as its spinal muscular atrophy drug, Spinraza, and rare disease treatment, Skyclarys, missed estimates.
The timing is crucial as the company navigates the slow pick-up of its keenly watched Alzheimer's Disease drug.
"Expectations are low so a decent quarter is good, but they need more... to get investors truly engaged and shift away from Leqembi," Jefferies analyst Michael Yee said in a note.
Biogenhas slashed jobs and pulled the plug on less promising drug candidates as part of aseries of cost-saving measures, as CEO Christopher Viehbacher takes the lead to bring the cash-strapped biotech back to growth.
The company has pinnedits hopes on newly launched treatments, including Leqembi, which has seen a slow pick-up in sales in the United States after concerns over cost, efficacy and side-effects.
"We don't believe that we have a demand issue. It is just taking the healthcare system time to actually adapt to treating this number of patients," Viehbacher said in a post-earnings call.
The drug was deemed too expensive for the UK's state-run health service in August. The EU regulator is expected to wrap up reexamining the drug's rejection this year, Biogen said.
Leqembi is also approved in China, Hong Kong, Israel, Japan and South Korea.
The drug, which the company sells with Eisai 4523.T, brought in about $67 million globally, beating estimates of $56 million, according to brokerage Piper Sandler.
Sales of newer treatments such as postpartum depression drug, Zurzuvae, andamyotrophic lateral sclerosis drug, Qalsody, beat estimates by $3 million and about $5 million, respectively. But Spinraza's $381.4 million sales missed an estimate of $430.5 million.
Biogen expects annual adjusted profit per share of $16.10 to$16.60, compared with a $15.75 to$16.25 per-share range previously. Itreported adjusted profit of $4.08 per share, topping an estimate of $3.79 per share.
Biogen shares fall as new Alzheimer's drug faces roadblocks outside U.S. https://tmsnrt.rs/48u6eQL
Reporting by Mariam Sunny in Bengaluru; Editing by Pooja Desai
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
